Literature DB >> 8765017

Lack of oral tolerance but oral priming for contact sensitivity to dinitrofluorobenzene in major histocompatibility complex class II-deficient mice and in CD4+ T cell-depleted mice.

C Desvignes1, H Bour, J F Nicolas, D Kaiserlian.   

Abstract

Oral tolerance is defined by immune unresponsiveness after oral administration of soluble antigens and by antigen-specific inhibition of peripheral immune responses induced by prior antigen feeding. The aim of this study was to investigate the implication of the major histocompatibility complex (MHC) class II presentation pathway to CD4+ T cells in oral tolerance of contact sensitivity (CS) to the hapten dinitrofluorobenzene (DNFB). We used MHC class II knockout (AB0/0) and invariant chain knockout (Ii0/0) mice, which have, respectively, a total or partial defect in class II-restricted activation of CD4+ T cells, as well as normal C57BL/6 mice depleted of CD4+ T cells by injection of a specific antibody. Intragastric administration of DNFB prior to skin sensitization induced specific inhibition of contact sensitivity to DNFB in A beta +/0 and Ii+/0 heterozygotes comparable to that observed in C57BL/6 mice. In contrast, no oral tolerance was observed in either MHC class II-deficient A beta 0/0 and Ii0/0 homozygote mutants or in syngeneic anti-CD4-depleted C57Bl/6 mice. Moreover, a single oral administration of DNFB, without skin sensitization, could prime A beta 0/0, Ii0/0 as well as anti-CD4-depleted C57BL/6 mice for DNFB-specific CS. These findings demonstrate that the class II/CD4 pathway is involved in oral tolerance manifested both as the inhibition of CS by hapten feeding prior to skin sensitization, and as immune unresponsiveness of normal mice to oral administration of hapten. Furthermore, our data provide evidence that a single oral feeding with DNFB is able to prime mice for hapten-specific CS, provided that the class II/ CD4 pathway is bypassed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8765017     DOI: 10.1002/eji.1830260814

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

Review 1.  Oral tolerance and gut-oriented immune response to dietary proteins.

Authors:  O Alpan
Journal:  Curr Allergy Asthma Rep       Date:  2001-11       Impact factor: 4.806

2.  Polarized expression of CD74 by gastric epithelial cells.

Authors:  Carlos A Barrera; Ellen J Beswick; Johanna C Sierra; David Bland; Rosario Espejo; Randy Mifflin; Patrick Adegboyega; Sheila E Crowe; Peter B Ernst; Victor E Reyes
Journal:  J Histochem Cytochem       Date:  2005-05-27       Impact factor: 2.479

Review 3.  Oral tolerance and the treatment of rheumatoid arthritis.

Authors:  H L Weiner; Y Komagata
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  Oral tolerance in disease.

Authors:  P Garside; A M Mowat; A Khoruts
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

Review 5.  Shifting the balance: antibiotic effects on host-microbiota mutualism.

Authors:  Benjamin P Willing; Shannon L Russell; B Brett Finlay
Journal:  Nat Rev Microbiol       Date:  2011-02-28       Impact factor: 60.633

Review 6.  Oral tolerance.

Authors:  W Strober; B Kelsall; T Marth
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

7.  The murine buccal mucosa is an inductive site for priming class I-restricted CD8+ effector T cells in vivo.

Authors:  C Desvignes; F Estèves; N Etchart; C Bella; C Czerkinsky; D Kaiserlian
Journal:  Clin Exp Immunol       Date:  1998-09       Impact factor: 4.330

8.  Tolerosome-induced oral tolerance is MHC dependent.

Authors:  Sofia Ostman; Maria Taube; Esbjörn Telemo
Journal:  Immunology       Date:  2005-12       Impact factor: 7.397

Review 9.  Induction of mucosal tolerance in SLE: a sniff or a sip away from ameliorating lupus?

Authors:  Henry Yim Wu
Journal:  Clin Immunol       Date:  2008-10-19       Impact factor: 3.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.